ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,401 to 1,420 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: serious adverse events948 of 3,256

927 of 3,248

0.6 points

-1.6 to 2.8

6,504NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

IV Rt-PA Cohort vs Non-reperfusion Cohort: deaths from any cause360 of 3,247

396 of 3,247

-1.1 points

-2.7 to 0.5

6,494NCT05395338

1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients

Ivabradine vs Placebo: serious adverse events1,369 of 3,232

1,481 of 3,260

-3.1 points

-5.5 to -0.7

6,492NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Pharmacist Arm vs Usual Care: deaths from any cause330 of 3,239

334 of 3,239

-0.1 points

-1.6 to 1.4

6,478NCT04071951

Pharmacist Intervention to Reduce Post-Hospitalization Utilization

Pharmacist Arm vs Usual Care: serious adverse events1,485 of 3,239

1,438 of 3,239

1.5 points

-1.0 to 3.9

6,478NCT04071951

Pharmacist Intervention to Reduce Post-Hospitalization Utilization

Empagliflozin 10 mg vs Placebo: serious adverse events765 of 3,234

798 of 3,229

-1.1 points

-3.1 to 1.0

6,463NCT04509674

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Apix 2.5mg BID vs Enox 40mg QD: serious adverse events611 of 3,184

601 of 3,217

0.5 points

-1.4 to 2.4

6,401NCT00457002

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Etanercept vs nbDMARDs: serious adverse events944 of 3,529

744 of 2,864

0.8 points

-1.4 to 2.9

6,393NCT01646385

Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry

Social Proof vs Reframing Side Effects and Adverse Reactions: Number of Employees Who Opened Emails After 3 Days1,481 of 3,198

1,398 of 3,190

2.5 points

0.0 to 4.9

6,388NCT04728594

Emails Promoting COVID-19 Vaccination Among Healthcare Workers

Social Proof vs Reframing Side Effects and Adverse Reactions: Number of Employees Who Clicked Scheduling Links After 3 Days562 of 3,198

382 of 3,190

5.6 points

3.9 to 7.3

6,388NCT04728594

Emails Promoting COVID-19 Vaccination Among Healthcare Workers

CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: deaths from any cause151 of 2,923

175 of 3,372

-0.0 points

-1.1 to 1.1

6,295NCT03890588

Chronic Kidney Disease Clinical Decision Support

CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: serious adverse events541 of 2,923

543 of 3,372

2.4 points

0.5 to 4.3

6,295NCT03890588

Chronic Kidney Disease Clinical Decision Support

Dapa 10 mg vs Placebo: Subjects Included in the Endpoint of All-cause Mortality497 of 3,131

526 of 3,132

-0.9 points

-2.8 to 0.9

6,263NCT03619213

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.512 of 3,131

610 of 3,132

-3.1 points

-5.0 to -1.2

6,263NCT03619213

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Dapa 10 mg vs Placebo: deaths from any cause510 of 3,131

533 of 3,132

-0.7 points

-2.6 to 1.1

6,263NCT03619213

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Dapa 10 mg vs Placebo: Subjects Included in the Endpoint of Cardiovascular Death231 of 3,131

261 of 3,132

-1.0 points

-2.3 to 0.4

6,263NCT03619213

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Dapa 10 mg vs Placebo: serious adverse events1,454 of 3,126

1,508 of 3,127

-1.7 points

-4.2 to 0.8

6,253NCT03619213

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Simvastatin Plus Ezetimibe vs Placebo: End-stage Renal Disease Among All Patients Not on Dialysis at the Time of Randomization to Simvastatin Plus Ezetimibe Versus Placebo1,057 of 3,117

1,084 of 3,130

-0.7 points

-3.1 to 1.6

6,247NCT00125593

Study of Heart and Renal Protection

FSC DPI vs FP DPI: Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period265 of 3,107

309 of 3,101

-1.4 points

-2.9 to 0.0

6,208NCT01462344

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

FSC DPI vs FP DPI: Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)27 of 3,107

21 of 3,101

0.2 points

-0.3 to 0.6

6,208NCT01462344

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=71

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02504216-sae",
        "title": "Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: serious adverse events",
        "summary": "948 of 3256 against 927 of 3248; risk difference 0.6 points, 95% interval -1.6 to 2.8; NCT02504216, Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities",
        "record": "/library/comparisons/NCT02504216-sae",
        "nct_id": "NCT02504216",
        "kind": "serious-adverse-events",
        "participants": 6504,
        "risk_difference": {
          "value": 0.005748387213904471,
          "lower": -0.01626477001928316,
          "upper": 0.027752744407118172
        },
        "group_1": "948 of 3,256",
        "group_2": "927 of 3,248",
        "difference": "0.6 points",
        "interval": "-1.6 to 2.8",
        "trial_title": "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities"
      },
      {
        "id": "NCT05395338-deaths",
        "title": "IV Rt-PA Cohort vs Non-reperfusion Cohort: deaths from any cause",
        "summary": "360 of 3247 against 396 of 3247; risk difference -1.1 points, 95% interval -2.7 to 0.5; NCT05395338, 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients",
        "record": "/library/comparisons/NCT05395338-deaths",
        "nct_id": "NCT05395338",
        "kind": "deaths",
        "participants": 6494,
        "risk_difference": {
          "value": -0.011087157376039422,
          "lower": -0.026706846379030563,
          "upper": 0.004524621804563027
        },
        "group_1": "360 of 3,247",
        "group_2": "396 of 3,247",
        "difference": "-1.1 points",
        "interval": "-2.7 to 0.5",
        "trial_title": "1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=72",
  "request_id": "nxcBjbS3eH-GqKT4"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?